ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Inhibition of phosphodiesterase: A novel therapeutic target for the treatment of mild cognitive impairment and Alzheimer's disease

Sheng, Jianwen; Zhang, Shanjin; Wu, Lule; Kumar, Gajendra; Liao, Yuanhang; Pratap, G. K.; Fan, Huizhen*
Frontiers in Aging Neuroscience2022-10-4DOI: 10.3389/fnagi.2022.1019187
6被引6阅读
引用收藏
分享

摘要

Alzheimer's disease (AD) is the most common form of dementia and is ranked as the 6th leading cause of death in the US. The prevalence of AD and dementia is steadily increasing and expected cases in USA is 14.8 million by 2050. Neuroinflammation and gradual neurodegeneration occurs in Alzheimer's disease. However, existing medications has limitation to completely abolish, delay, or prevent disease progression. Phosphodiesterases (PDEs) are large family of enzymes to hydrolyze the 3'-phosphodiester links in cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) in signal-transduction pathways for generation of 5'-cyclic nucleotides. It plays vital role to orchestrate several pharmacological activities for proper cell functioning and regulating the levels of cAMP and cGMP. Several evidence has suggested that abnormal cAMP signaling is linked to cognitive problems in neurodegenerative disorders like AD. Therefore, the PDE family has become a widely accepted and multipotential therapeutic target for neurodegenerative diseases. Notably, modulation of cAMP/cGMP by phytonutrients has a huge potential for the management of AD. Natural compounds have been known to inhibit phosphodiesterase by targeting key enzymes of cGMP synthesis pathway, however, the mechanism of action and their therapeutic efficacy has not been explored extensively. Currently, few PDE inhibitors such as Vinpocetine and Nicergoline have been used for treatment of central nervous system (CNS) disorders. Considering the role of flavonoids to inhibit PDE, this review discussed the therapeutic potential of natural compounds with PDE inhibitory activity for the treatment of AD and related dementia.

学科与关键词

关键词
natural productsphosphodiesteraseAlzheimer's diseasecyclic-AMPVinpocetine
相关
加载中…
  • Potential therapeutic use of plant flavonoids in AD and PD
    Meng-Zhen, Sun; Ju, Li; Lan-Chun, Zhang; Cai-Feng, Ding; Shu-Da, Yang; Hao-Fei, Yu*; Wei-Yan, Hu*Heliyon, 2022, 8(11): e11440.被引 9
  • 磷酸二酯酶:从伟哥到抗阿尔茨海默病药物
    王浩; 周延萌; 侯雪芹; 张芳芳; 赵晓民; 张汉霆中国药理学与毒理学杂志, 2019, (10): 790.
  • The Multifunctional Anti-inflammatory Drugs Used in the Therapy of Alzheimer's Disease
    Shi, S.; Wang, Z.; Qiao, Z.*Current Medicinal Chemistry, 2013, 20(20): 2583-2588.被引 15
查看全部 →

发表信息

论文状态
公开发表
期刊
Frontiers in Aging Neuroscience
发表日期
2022-10-04
卷期
第 14 卷
页码
1019187
DOI
10.3389/fnagi.2022.1019187
语言
ENGLISH
期刊等级
2区
成果收录
SCIE

作者

  • S

    Sheng, Jianwen (第一作者)

  • Z

    Zhang, Shanjin

查看全部 7 位作者收起作者
  • W

    Wu, Lule

  • K

    Kumar, Gajendra

  • L

    Liao, Yuanhang

  • P

    Pratap, G. K.

  • F

    Fan, Huizhen (通讯)

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417